NCT04449276 is a Phase 1 clinical trial of CVnCoV Vaccine in Severe Acute Respiratory Syndrome, sponsored by CureVac.

Who is sponsoring NCT04449276?

NCT04449276 is sponsored by CureVac.

What drugs are being tested in NCT04449276?

Interventions in NCT04449276: CVnCoV Vaccine, Placebo.

What condition does NCT04449276 study?

NCT04449276 studies Severe Acute Respiratory Syndrome, Coronavirus, SARS-CoV-2, COVID-19.

Is NCT04449276 still recruiting?

NCT04449276 is currently completed. Last updated 30 January 2023.

Are results published for NCT04449276?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2023-01-30 · How we verify

NCT04449276

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19

Completed Phase 1 Results posted Last updated 30 January 2023

What this trial tests

Phase 1 trial testing CVnCoV Vaccine in Severe Acute Respiratory Syndrome in 280 participants. Completed in 21 December 2021.

Timeline

18 June 2020

Primary endpoint
21 December 2021

21 December 2021

Quick facts

Lead sponsor	CureVac
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	sequential
Masking	single
Primary purpose	prevention
Enrollment	280
Start date	18 June 2020
Primary completion	21 December 2021
Estimated completion	21 December 2021
Sites	4 locations across Belgium, Germany

Drugs / interventions tested

CVnCoV Vaccine — full drug profile →
Placebo

Conditions studied

Severe Acute Respiratory Syndrome — all drugs for Severe Acute Respiratory Syndrome →
Coronavirus — all drugs for Coronavirus →
SARS-CoV-2 — all drugs for SARS-CoV-2 →
COVID-19 — all drugs for COVID-19 →

Sponsor

CureVac — full company profile →

Who can join

Adults 18 to 60, any sex, with Severe Acute Respiratory Syndrome or Coronavirus. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Number of Participants With Grade 3 Adverse Reactions or Any Serious Adverse Event (SAE) Considered Related to Trial Vaccine Within at Least 24 Hours After the First Vaccination Primary · Up to 24 hours after vaccination on Day 1

Grade 3 refers to the highest grading on the FDA toxicity scale where a higher grade indicates a worse outcome. An SAE was defined as any untoward medical occurrence that, at any dose: * Resulted in death. * Was life-threatening. * Required inpatient hospitalization or prolongation of existing hospitalization. * Resulted in persistent disability/incapacity. * Was a congenital anomaly/birth defect in the offspring of the participant. * Was an important medical event.

Any Grade 3 Adverse Reaction

Group	Value	95% CI
Dose Escalation CVnCoV: 2 µg	3
Dose Escalation CVnCoV: 4 µg	9
Dose Escalation CVnCoV: 6 µg	8
Dose Escalation CVnCoV: 8 µg	14
Dose Escalation CVnCoV: 12 µg	12
Dose Escalation CVnCoV: 16 µg	7
Dose Escalation CVnCoV: 20 µg	8
Dose Escalation Placebo	0

Any Serious Adverse Event (SAE) Considered Related to Trial Vaccine

Group	Value	95% CI
Dose Escalation CVnCoV: 2 µg	0
Dose Escalation CVnCoV: 4 µg	0
Dose Escalation CVnCoV: 6 µg	0
Dose Escalation CVnCoV: 8 µg	0
Dose Escalation CVnCoV: 12 µg	0
Dose Escalation CVnCoV: 16 µg	0
Dose Escalation CVnCoV: 20 µg	0
Dose Escalation Placebo	0

Number of Participants With Grade 3 Adverse Reactions or Any Serious Adverse Event (SAE) Considered Related to Trial Vaccine Within at Least 60 Hours After the First Vaccination Primary · Up to 60 hours after vaccination on Day 1

Any Grade 3 Adverse Reaction

Group	Value	95% CI
Dose Escalation CVnCoV: 2 µg	3
Dose Escalation CVnCoV: 4 µg	9
Dose Escalation CVnCoV: 6 µg	8
Dose Escalation CVnCoV: 8 µg	14
Dose Escalation CVnCoV: 12 µg	12
Dose Escalation CVnCoV: 16 µg	7
Dose Escalation CVnCoV: 20 µg	8
Dose Escalation Placebo	0

Any Serious Adverse Event (SAE) Considered Related to Trial Vaccine

Group	Value	95% CI
Dose Escalation CVnCoV: 2 µg	0
Dose Escalation CVnCoV: 4 µg	0
Dose Escalation CVnCoV: 6 µg	0
Dose Escalation CVnCoV: 8 µg	0
Dose Escalation CVnCoV: 12 µg	0
Dose Escalation CVnCoV: 16 µg	0
Dose Escalation CVnCoV: 20 µg	0
Dose Escalation Placebo	0

Number of Participants With Solicited Local Adverse Events Primary · Up to 7 days after vaccination (Days 1 to 8 and Day 29 to 36)

Reactogenicity was assessed daily via collection of solicited local AEs (injection site pain, redness, swelling, and itching) using paper diary cards.

Group	Value	95% CI
Dose Escalation CVnCoV: 2 µg	32
Dose Escalation CVnCoV: 4 µg	43
Dose Escalation CVnCoV: 6 µg	38
Dose Escalation CVnCoV: 8 µg	41
Dose Escalation CVnCoV: 12 µg	26
Dose Escalation CVnCoV: 16 µg	16
Dose Escalation CVnCoV: 20 µg	11
Dose Escalation Placebo	5

Intensity of Solicited Local Adverse Events Per the FDA Toxicity Grading Scale Primary · Up to 7 days after vaccination (Days 1 to 8 and Days 29 to 36)

Reactogenicity was assessed daily via collection of solicited local AEs (injection site pain, redness, swelling, and itching) using paper diary cards. Intensity of solicited local AEs and solicited systemic AEs were graded per the FDA Toxicity Grading Scale at Grades 1-3, where higher grades indicate a worse outcome.

Grade 1

Group	Value	95% CI
Dose Escalation CVnCoV: 2 µg	30
Dose Escalation CVnCoV: 4 µg	39
Dose Escalation CVnCoV: 6 µg	32
Dose Escalation CVnCoV: 8 µg	29
Dose Escalation CVnCoV: 12 µg	17
Dose Escalation CVnCoV: 16 µg	12
Dose Escalation CVnCoV: 20 µg	6
Dose Escalation Placebo	5

Grade 2

Group	Value	95% CI
Dose Escalation CVnCoV: 2 µg	2
Dose Escalation CVnCoV: 4 µg	3
Dose Escalation CVnCoV: 6 µg	5
Dose Escalation CVnCoV: 8 µg	11
Dose Escalation CVnCoV: 12 µg	9
Dose Escalation CVnCoV: 16 µg	4
Dose Escalation CVnCoV: 20 µg	5
Dose Escalation Placebo	0

Grade 3

Group	Value	95% CI
Dose Escalation CVnCoV: 2 µg	0
Dose Escalation CVnCoV: 4 µg	1
Dose Escalation CVnCoV: 6 µg	1
Dose Escalation CVnCoV: 8 µg	1
Dose Escalation CVnCoV: 12 µg	0
Dose Escalation CVnCoV: 16 µg	0
Dose Escalation CVnCoV: 20 µg	0
Dose Escalation Placebo	0

Duration of Solicited Local Adverse Events Primary · Up to 7 days after vaccination (Days 1 to 8 and Days 29 to 36)

Reactogenicity was assessed daily via collection of solicited local AEs (injection site pain, redness, swelling, and itching) using paper diary cards. Duration was calculated as consecutive days with a respective solicited AE regardless of the grade of the AE.

Group	Value	95% CI
Dose Escalation CVnCoV: 2 µg	1.8	± 0.99
Dose Escalation CVnCoV: 4 µg	2.0	± 0.84
Dose Escalation CVnCoV: 6 µg	2.3	± 1.02
Dose Escalation CVnCoV: 8 µg	2.4	± 1.44
Dose Escalation CVnCoV: 12 µg	2.6	± 1.44
Dose Escalation CVnCoV: 16 µg	2.5	± 0.82
Dose Escalation CVnCoV: 20 µg	3.0	± 1.18
Dose Escalation Placebo	1.2	± 0.45

Number of Participants With Solicited Systemic Adverse Events Primary · Up to 7 days after vaccination (Days 1 to 8 and Days 29 to 36)

Reactogenicity was assessed daily via collection of solicited systemic AEs (fever, headache, fatigue, chills, myalgia, arthralgia, nausea/vomiting, and diarrhea) using paper diary cards.

Group	Value	95% CI
Dose Escalation CVnCoV: 2 µg	29
Dose Escalation CVnCoV: 4 µg	45
Dose Escalation CVnCoV: 6 µg	44
Dose Escalation CVnCoV: 8 µg	45
Dose Escalation CVnCoV: 12 µg	28
Dose Escalation CVnCoV: 16 µg	16
Dose Escalation CVnCoV: 20 µg	12
Dose Escalation Placebo	19

Intensity of Solicited Systemic Adverse Events Per the FDA Toxicity Grading Scale Primary · Up to 7 days after vaccination (Days 1 to 8 and Days 29 to 36)

Reactogenicity was assessed daily via collection of solicited systemic AEs (fever, headache, fatigue, chills, myalgia, arthralgia, nausea/vomiting, and diarrhea) using paper diary cards. Intensity of solicited local AEs and solicited systemic AEs were graded per the FDA Toxicity Grading Scale at Grades 1-3, where higher grades indicate a worse outcome.

Grade 1

Group	Value	95% CI
Dose Escalation CVnCoV: 2 µg	21
Dose Escalation CVnCoV: 4 µg	22
Dose Escalation CVnCoV: 6 µg	20
Dose Escalation CVnCoV: 8 µg	11
Dose Escalation CVnCoV: 12 µg	1
Dose Escalation CVnCoV: 16 µg	2
Dose Escalation CVnCoV: 20 µg	0
Dose Escalation Placebo	15

Grade 2

Group	Value	95% CI
Dose Escalation CVnCoV: 2 µg	5
Dose Escalation CVnCoV: 4 µg	14
Dose Escalation CVnCoV: 6 µg	16
Dose Escalation CVnCoV: 8 µg	20
Dose Escalation CVnCoV: 12 µg	16
Dose Escalation CVnCoV: 16 µg	7
Dose Escalation CVnCoV: 20 µg	5
Dose Escalation Placebo	4

Grade 3

Group	Value	95% CI
Dose Escalation CVnCoV: 2 µg	3
Dose Escalation CVnCoV: 4 µg	9
Dose Escalation CVnCoV: 6 µg	8
Dose Escalation CVnCoV: 8 µg	14
Dose Escalation CVnCoV: 12 µg	11
Dose Escalation CVnCoV: 16 µg	7
Dose Escalation CVnCoV: 20 µg	7
Dose Escalation Placebo	0

Duration of Solicited Systemic Adverse Events Primary · Up to 7 days after vaccination (Days 1 to 8 and Days 29 to 36)

Reactogenicity was assessed daily via collection of solicited systemic AEs (fever, headache, fatigue, chills, myalgia, arthralgia, nausea/vomiting, and diarrhea) using paper diary cards. Duration was calculated as consecutive days with a respective solicited AE regardless of the grade of the AE.

Group	Value	95% CI
Dose Escalation CVnCoV: 2 µg	3.1	± 5.38
Dose Escalation CVnCoV: 4 µg	2.1	± 1.15
Dose Escalation CVnCoV: 6 µg	2.4	± 2.16
Dose Escalation CVnCoV: 8 µg	3.2	± 2.40
Dose Escalation CVnCoV: 12 µg	3.6	± 1.73
Dose Escalation CVnCoV: 16 µg	2.5	± 0.73
Dose Escalation CVnCoV: 20 µg	3.4	± 1.24
Dose Escalation Placebo	1.8	± 0.96

Number of Participants With Solicited Systemic Adverse Events Considered Related to Trial Vaccine Primary · Up to 7 days after vaccination (Days 1 to 8 and Days 29 to 36)

Reactogenicity was assessed daily via collection of solicited systemic AEs (fever, headache, fatigue, chills, myalgia, arthralgia, nausea/vomiting, and diarrhea) using paper diary cards. The Investigator assessed the relationship between trial vaccine and each occurrence of each AE.

Group	Value	95% CI
Dose Escalation CVnCoV: 2 µg	28
Dose Escalation CVnCoV: 4 µg	45
Dose Escalation CVnCoV: 6 µg	44
Dose Escalation CVnCoV: 8 µg	44
Dose Escalation CVnCoV: 12 µg	28
Dose Escalation CVnCoV: 16 µg	16
Dose Escalation CVnCoV: 20 µg	12
Dose Escalation Placebo	17

Number of Participants With Unsolicited Adverse Events Primary · Up to 28 days after vaccination (Days 1 to 29 and Days 29 to 57)

Group	Value	95% CI
Dose Escalation CVnCoV: 2 µg	26
Dose Escalation CVnCoV: 4 µg	32
Dose Escalation CVnCoV: 6 µg	29
Dose Escalation CVnCoV: 8 µg	31
Dose Escalation CVnCoV: 12 µg	23
Dose Escalation CVnCoV: 16 µg	13
Dose Escalation CVnCoV: 20 µg	11
Dose Escalation Placebo	16

Intensity of Unsolicited Adverse Events Assessed by the Investigator Primary · Up to 28 days after vaccination (Days 1 to 29 and Days 29 to 57)

Diaries were used for collection of unsolicited AEs on each vaccination day and the following 28 days. In addition, participants were contacted by phone to verify whether they had any health concerns since the last visit. Participants were included only once, at the maximum severity. The Investigator made an assessment of intensity for each AE reported during the trial and assigned it to one of the following categories: * Mild: an event that was easily tolerated by the participant, causing minimal discomfort and not interfering with everyday activities. * Moderate: an event that caused suffic

Mild

Group	Value	95% CI
Dose Escalation CVnCoV: 2 µg	14
Dose Escalation CVnCoV: 4 µg	17
Dose Escalation CVnCoV: 6 µg	15
Dose Escalation CVnCoV: 8 µg	12
Dose Escalation CVnCoV: 12 µg	9
Dose Escalation CVnCoV: 16 µg	8
Dose Escalation CVnCoV: 20 µg	4
Dose Escalation Placebo	9

Moderate

Group	Value	95% CI
Dose Escalation CVnCoV: 2 µg	10
Dose Escalation CVnCoV: 4 µg	13
Dose Escalation CVnCoV: 6 µg	10
Dose Escalation CVnCoV: 8 µg	17
Dose Escalation CVnCoV: 12 µg	10
Dose Escalation CVnCoV: 16 µg	5
Dose Escalation CVnCoV: 20 µg	2
Dose Escalation Placebo	6

Severe

Group	Value	95% CI
Dose Escalation CVnCoV: 2 µg	2
Dose Escalation CVnCoV: 4 µg	2
Dose Escalation CVnCoV: 6 µg	4
Dose Escalation CVnCoV: 8 µg	2
Dose Escalation CVnCoV: 12 µg	4
Dose Escalation CVnCoV: 16 µg	0
Dose Escalation CVnCoV: 20 µg	5
Dose Escalation Placebo	1

Number of Participants With Unsolicited Adverse Events Considered Related to Trial Vaccine Primary · Up to 28 days after vaccination (Days 1 to 29 and Days 29 to 57)

Group	Value	95% CI
Dose Escalation CVnCoV: 2 µg	7
Dose Escalation CVnCoV: 4 µg	20
Dose Escalation CVnCoV: 6 µg	15
Dose Escalation CVnCoV: 8 µg	16
Dose Escalation CVnCoV: 12 µg	12
Dose Escalation CVnCoV: 16 µg	4
Dose Escalation CVnCoV: 20 µg	10
Dose Escalation Placebo	5

Adverse events — posted to ClinicalTrials.gov

Time frame: Day 1 up to Day 393. Reporting threshold: 5%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Dose Escalation CVnCoV: 2 µg

Serious: 2/47 (4%)

Deaths: 0/47

Dose Escalation CVnCoV: 4 µg

Serious: 0/48 (0%)

Deaths: 0/48

Dose Escalation CVnCoV: 6 µg

Serious: 1/48 (2%)

Deaths: 0/48

Dose Escalation CVnCoV: 8 µg

Serious: 1/49 (2%)

Deaths: 0/49

Dose Escalation CVnCoV: 12 µg

Serious: 2/28 (7%)

Deaths: 0/28

Dose Escalation CVnCoV: 16 µg

Serious: 0/16 (0%)

Deaths: 0/16

Dose Escalation CVnCoV: 20 µg

Serious: 0/12 (0%)

Deaths: 0/12

Dose Escalation Placebo

Serious: 1/32 (3%)

Deaths: 0/32

Serious adverse events (8 terms)

Reaction	System	Dose Escalation CVnCoV: 2 µg	Dose Escalation CVnCoV: 4 µg	Dose Escalation CVnCoV: 6 µg	Dose Escalation CVnCoV: 8 µg	Dose Escalation CVnCoV: 12…	Dose Escalation CVnCoV: 16…	Dose Escalation CVnCoV: 20…	Dose Escalation Placebo
Abdominal pain	Gastrointestinal disorders	—	—	—	—	—	—	—	—
Crohn's disease	Gastrointestinal disorders	—	—	—	—	—	—	—	—
Peroneal nerve palsy	Nervous system disorders	—	—	—	—	—	—	—	—
Seizure	Nervous system disorders	—	—	—	—	—	—	—	—
Retinal detachment	Eye disorders	—	—	—	—	—	—	—	—
Retinal disorder	Eye disorders	—	—	—	—	—	—	—	—
COVID-19	Infections and infestations	—	—	—	—	—	—	—	—
Humerus fracture	Injury, poisoning and procedural complications	—	—	—	—	—	—	—	—

Other adverse events (62 terms — click to expand)

Reaction	System	Dose Escalation CVnCoV: 2 µg	Dose Escalation CVnCoV: 4 µg	Dose Escalation CVnCoV: 6 µg	Dose Escalation CVnCoV: 8 µg	Dose Escalation CVnCoV: 12…	Dose Escalation CVnCoV: 16…	Dose Escalation CVnCoV: 20…	Dose Escalation Placebo
Headache	Nervous system disorders	—	—	—	—	—	—	—	—
Dizziness	Nervous system disorders	—	—	—	—	—	—	—	—
Oropharyngeal pain	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—	—	—
Cough	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—	—	—
Fatigue	General disorders	—	—	—	—	—	—	—	—
Feeling hot	General disorders	—	—	—	—	—	—	—	—
Malaise	General disorders	—	—	—	—	—	—	—	—
Diarrhoea	Gastrointestinal disorders	—	—	—	—	—	—	—	—
Back pain	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—	—	—
Lymphopenia	Blood and lymphatic system disorders	—	—	—	—	—	—	—	—
Tachycardia	Cardiac disorders	—	—	—	—	—	—	—	—
Dysmerorrhoea	Reproductive system and breast disorders	—	—	—	—	—	—	—	—
Nasopharyngitis	Infections and infestations	—	—	—	—	—	—	—	—
Upper respiratory tract infection	Infections and infestations	—	—	—	—	—	—	—	—
Oral Herpes	Infections and infestations	—	—	—	—	—	—	—	—
COVID-19	Infections and infestations	—	—	—	—	—	—	—	—
Cystitis	Infections and infestations	—	—	—	—	—	—	—	—
Pharyngitis	Infections and infestations	—	—	—	—	—	—	—	—
Tooth infection	Infections and infestations	—	—	—	—	—	—	—	—
Gingivitis	Infections and infestations	—	—	—	—	—	—	—	—
Pyrexia	General disorders	—	—	—	—	—	—	—	—
Rhinorrhoea	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—	—	—
Nausea	Gastrointestinal disorders	—	—	—	—	—	—	—	—
Neck pain	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—	—	—
Arthropod sting	Injury, poisoning and procedural complications	—	—	—	—	—	—	—	—
Hyperhidrosis	Skin and subcutaneous tissue disorders	—	—	—	—	—	—	—	—
Lymphadenopathy	Blood and lymphatic system disorders	—	—	—	—	—	—	—	—
Leukopenia	Blood and lymphatic system disorders	—	—	—	—	—	—	—	—
Gamma-glutamyltransferase increased	Investigations	—	—	—	—	—	—	—	—
Decreased appetite	Metabolism and nutrition disorders	—	—	—	—	—	—	—	—
Hypertension	Vascular disorders	—	—	—	—	—	—	—	—
Hot flush	Vascular disorders	—	—	—	—	—	—	—	—
Asthenopia	Eye disorders	—	—	—	—	—	—	—	—
Vertigo	Ear and labyrinth disorders	—	—	—	—	—	—	—	—
Rhinitis	Infections and infestations	—	—	—	—	—	—	—	—
Bronchitis	Infections and infestations	—	—	—	—	—	—	—	—
Enterobiasis	Infections and infestations	—	—	—	—	—	—	—	—
Epstein-Barr virus infection	Infections and infestations	—	—	—	—	—	—	—	—
Taste disorder	Nervous system disorders	—	—	—	—	—	—	—	—
Morton's neuralgia	Nervous system disorders	—	—	—	—	—	—	—	—

Most-reported serious reactions: Abdominal pain, Crohn's disease, Peroneal nerve palsy, Seizure, Retinal detachment, Retinal disorder, COVID-19, Humerus fracture.

Data from ClinicalTrials.gov NCT04449276 adverse events section.

Sponsor's own description

This study aims to evaluate the safety and reactogenicity profile after 1 and 2 dose administrations of CVnCoV at different dose levels.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

mRNA vaccines for infectious diseases: principles, delivery and clinical translation.
Chaudhary N, Weissman D, Whitehead KA. · · 2021 · cited 1014× · PMID 34433919 · DOI 10.1038/s41573-021-00283-5
Immunological considerations for COVID-19 vaccine strategies.
Jeyanathan M, Afkhami S, Smaill F, Miller MS, et al · · 2020 · cited 697× · PMID 32887954 · DOI 10.1038/s41577-020-00434-6
SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates.
Poland GA, Ovsyannikova IG, Kennedy RB. · · 2020 · cited 463× · PMID 33065034 · DOI 10.1016/s0140-6736(20)32137-1
Self-assembled mRNA vaccines.
Kim J, Eygeris Y, Gupta M, Sahay G. · · 2021 · cited 371× · PMID 33400957 · DOI 10.1016/j.addr.2020.12.014
Advances in COVID-19 mRNA vaccine development.
Fang E, Liu X, Li M, Zhang Z, et al · · 2022 · cited 368× · PMID 35322018 · DOI 10.1038/s41392-022-00950-y
mRNA vaccine: a potential therapeutic strategy.
Wang Y, Zhang Z, Luo J, Han X, et al · · 2021 · cited 286× · PMID 33593376 · DOI 10.1186/s12943-021-01311-z
COVID-19 vaccines: rapid development, implications, challenges and future prospects.
Kashte S, Gulbake A, El-Amin Iii SF, Gupta A. · · 2021 · cited 240× · PMID 33677814 · DOI 10.1007/s13577-021-00512-4
COVID-19 vaccines: The status and perspectives in delivery points of view.
Chung JY, Thone MN, Kwon YJ. · · 2021 · cited 240× · PMID 33359141 · DOI 10.1016/j.addr.2020.12.011

Verify or expand the search:

Other trials of CVnCoV Vaccine

Trials testing the same drug.

NCT04860258 — COVID-19: A Study to Evaluate Safety, Reactogenicity and Immunogenicity of the SARS-CoV-2 mRNA Vaccine CVnCoV in Adults · Phase 3 · terminated
NCT04674189 — A Study to Evaluate the Safety and Immunogenicity of Vaccine CVnCoV in Healthy Adults in Germany for COVID-19 · Phase 3 · completed

Other CureVac trials

Trials by the same sponsor.

NCT07073183 — Safety and Tolerability of CVHNLC Plus Pembrolizumab in Patients With Squamous Non Small-Cell Lung Cancer (sqNSCLC) · Phase 1 · not yet recruiting
NCT05938387 — Safety and Tolerability of CVGBM in Adults With Newly Diagnosed MGMT-Unmethylated Glioblastoma or Astrocytoma · Phase 1 · completed
NCT05252338 — A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVSQIV in Healthy Adults · Phase 1 · completed
NCT04860258 — COVID-19: A Study to Evaluate Safety, Reactogenicity and Immunogenicity of the SARS-CoV-2 mRNA Vaccine CVnCoV in Adults · Phase 3 · terminated
NCT04674189 — A Study to Evaluate the Safety and Immunogenicity of Vaccine CVnCoV in Healthy Adults in Germany for COVID-19 · Phase 3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04449276 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by CureVac
Last refreshed: 30 January 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04449276.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing